You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)公布百澤安用於治療二線或三線非小細胞肺癌之臨床試驗中期分析結果
阿思達克 04-13 08:54
百濟神州(06160.HK)公布,於今年4月12日在美國癌症研究協會(AACR)2021年年會上的一項口頭報告中公佈了其抗PD-1抗體百澤安(替雷利珠單抗)對比多西他賽針對二線或三線局部晚期或轉移性非小細胞肺癌(NSCLC)患者的全球3期臨床試驗的中期分析結果。基於此項試驗結果的新適應症上市申請(sBLA)已於2021年3月在中國獲受理,目前正在接受審評。

公司指,結果證明百澤安有望為二線或三線局部晚期或轉移性NSCLC患者帶來生存益處,這與集團在去年的ASCO以及ESMO年會上公佈針對初治患者的兩項試驗結果相一致。此外,百澤安總體耐受,與先前在其他多項腫瘤中公佈的結果和已知風險相符。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account